Research Topics
| Brian R MurphySummaryAffiliation: National Institutes of Health Country: USA Publications
| Collaborators
|
Detail Information
Publications
Tahyna virus genetics, infectivity, and immunogenicity in mice and monkeysRichard S Bennett
Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
Virol J 8:135. 2011..Human infections are frequent with neutralizing antibodies present in 60-80% of the elderly population in endemic areas...- The full genome sequence of three strains of Jamestown Canyon virus and their pathogenesis in mice or monkeysRichard S Bennett
Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
Virol J 8:136. 2011..The virus is genetically similar to Inkoo virus circulating in Europe, suggesting that much of the northern hemisphere contains JCV or similar variants... - Attenuation and efficacy of human parainfluenza virus type 1 (HPIV1) vaccine candidates containing stabilized mutations in the P/C and L genesEmmalene J Bartlett
Laboratory of Infectious Diseases, Respiratory Viruses Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, USA
Virol J 4:67. 2007..These mutations were evaluated on the HPIV1 backbone, both individually and in combination, for attenuation, immunogenicity, and protective efficacy in African green monkeys (AGMs)... - Impairment of the CD8+ T cell response in lungs following infection with human respiratory syncytial virus is specific to the anatomical site rather than the virus, antigen, or route of infectionJoshua M DiNapoli
Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
Virol J 5:105. 2008..It was suggested that the impairment specifically suppressed the host cellular immune response, a finding that could help explain the ability of RSV to re-infect throughout life... - La Crosse virus infectivity, pathogenesis, and immunogenicity in mice and monkeysRichard S Bennett
Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
Virol J 5:25. 2008..As an initial step in the establishment of useful animal models to support vaccine development, we examined LACV infectivity, pathogenesis, and immunogenicity in both weanling mice and rhesus monkeys... - Vaccine candidates for dengue virus type 1 (DEN1) generated by replacement of the structural genes of rDEN4 and rDEN4Delta30 with those of DEN1Joseph E Blaney
Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
Virol J 4:23. 2007.... - Genome sequence analysis of La Crosse virus and in vitro and in vivo phenotypesRichard S Bennett
Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
Virol J 4:41. 2007..The majority of LACV infections are mild and never reported, however, serologic studies estimate infection rates of 10-30/100,000 in endemic areas... - Vaccine candidates derived from a novel infectious cDNA clone of an American genotype dengue virus type 2Joseph E Blaney
Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892 USA
BMC Infect Dis 4:39. 2004..To prepare a vaccine candidate, a previously described 30 nucleotide deletion (Delta30) in the 3' untranslated region of DEN-4 has been engineered into the DEN-2 isolate... - Infection of nonhuman primates with recombinant human metapneumovirus lacking the SH, G, or M2-2 protein categorizes each as a nonessential accessory protein and identifies vaccine candidatesStephane Biacchesi
National Institutes of Health, NIAID, Laboratory of Infectious Diseases, Bethesda, MD 20892 8007, USA
J Virol 79:12608-13. 2005..The deltaG and deltaM2-2 viruses are promising vaccine candidates that are based on independent mechanisms of attenuation and are appropriate for clinical evaluation... - Chimeric recombinant human metapneumoviruses with the nucleoprotein or phosphoprotein open reading frame replaced by that of avian metapneumovirus exhibit improved growth in vitro and attenuation in vivoQuynh N Pham
Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892 8007, USA
J Virol 79:15114-22. 2005..Both chimeras were comparable to wild-type HMPV in immunogenicity and protective efficacy. Thus, the P chimera is a promising live HMPV vaccine candidate that paradoxically combines improved growth in vitro with attenuation in vivo... 
Infectivity of West Nile/dengue chimeric viruses for West Nile and dengue mosquito vectorsKathryn A Hanley
Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
Vector Borne Zoonotic Dis 5:1-10. 2005..This restriction in potential vectors renders it less likely that WN/DEN4 and WN/DEN4-3'delta30 would be transmitted from vaccinees to mosquitoes...- Generation of recombinant human parainfluenza virus type 1 vaccine candidates by importation of temperature-sensitive and attenuating mutations from heterologous paramyxovirusesJason T Newman
Respiratory Viruses Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
J Virol 78:2017-28. 2004..Thus, importation of attenuating mutations from heterologous viruses is an effective means for rapidly identifying mutations that attenuate HPIV1 and for generating live-attenuated HPIV1 vaccine candidates... - Evaluation of St. Louis encephalitis virus/dengue virus type 4 antigenic chimeric viruses in mice and rhesus monkeysJoseph E Blaney
Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 3203, USA
Vaccine 26:4150-9. 2008..These viruses may be considered for use as SLE vaccine candidates and for use as diagnostic reagents with reduced virulence... - Introduction of mutations into the non-structural genes or 3' untranslated region of an attenuated dengue virus type 4 vaccine candidate further decreases replication in rhesus monkeys while retaining protective immunityKathryn A Hanley
Laboratory of Infectious Diseases (LID, National Institute of Allergy and Infectious Diseases (NIAID, National Institutes of Health (NIH, Building 50, Room 6515, 50 South Drive, MSC 8007, Bethesda, MD 20892-8007, USA
Vaccine 22:3440-8. 2004..The application of these attenuating mutations to flavivirus vaccine development is discussed... - An improved method for the recovery of recombinant paramyxovirus vaccine candidates suitable for use in human clinical trialsSonja R Surman
Laboratory of Infectious Diseases, Respiratory Viruses Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
J Virol Methods 141:30-3. 2007..Since it is likely that all live-attenuated parainfluenza virus and pneumovirus vaccines in the future will be generated using reverse genetics, this simplified method provides guidance on how this can be achieved... - A tick-borne Langat virus mutant that is temperature sensitive and host range restricted in neuroblastoma cells and lacks neuroinvasiveness for immunodeficient miceAlexander A Rumyantsev
Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases/NIH, 12735 Twinbrook Parkway, Twinbrook 3, Room 3W13, MSC 8133, Bethesda, MD 20892-8133, USA
J Virol 80:1427-39. 2006..An evaluation of the complete sequence of virus recovered from brain of SCID mice inoculated with LGT mutants identified sites in the LGT genome that promoted neurovirulence/neuroinvasiveness... - A DNA vaccine induces SARS coronavirus neutralization and protective immunity in miceZhi-Yong Yang
Vaccine Research Center, NIAID, National Institutes of Health, Building 40, Room 4502, MSC-3005, 40 Convent Drive, Bethesda, Maryland 20892-3005, USA
Nature 428:561-4. 2004..Gene-based vaccination for the SARS-CoV elicits effective immune responses that generate protective immunity in an animal model... - Mutations which enhance the replication of dengue virus type 4 and an antigenic chimeric dengue virus type 2/4 vaccine candidate in Vero cellsJoseph E Blaney
Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Building 50, Room 6515, 50 South Drive, MSC 8007, Bethesda, MD 20892-8007, USA
Vaccine 21:4317-27. 2003..The importance of these Vero cell adaptation mutations in flavivirus vaccine design and development is discussed... - A novel human parainfluenza virus type 1 (HPIV1) with separated P and C genes is useful for generating C gene mutants for evaluation as live-attenuated virus vaccine candidatesEmmalene J Bartlett
Laboratory of Infectious Diseases, RNA Viruses Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892 2007, USA
Vaccine 28:767-79. 2010..rHPIV1-C(Delta 84-85)+P will be investigated as a potential live-attenuated vaccine candidate for HPIV1... - Codon substitution mutations at two positions in the L polymerase protein of human parainfluenza virus type 1 yield viruses with a spectrum of attenuation in vivo and increased phenotypic stability in vitroJosephine M McAuliffe
Respiratory Viruses Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
J Virol 78:2029-36. 2004..These findings identify the use of alternative codon substitution mutations as a method that can be used to generate candidate vaccine viruses with increased genetic stability and/or a modified level of attenuation... - Recombinant human Metapneumovirus lacking the small hydrophobic SH and/or attachment G glycoprotein: deletion of G yields a promising vaccine candidateStephane Biacchesi
Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland 20892 8007, USA
J Virol 78:12877-87. 2004..This indicates that SH is completely dispensable in vivo and that its deletion does not confer an attenuating effect, at least in this rodent model... - Recombinant respiratory syncytial virus with the G and F genes shifted to the promoter-proximal positionsChristine Krempl
Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland 20892-8007, USA
J Virol 76:11931-42. 2002.... - Recombinant human parainfluenza virus type 2 vaccine candidates containing a 3' genomic promoter mutation and L polymerase mutations are attenuated and protective in non-human primatesSheila M Nolan
Laboratory of Infectious Diseases, Respiratory Viruses Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
Vaccine 25:6409-22. 2007.... - Human parainfluenza virus type 1 C proteins are nonessential proteins that inhibit the host interferon and apoptotic responses and are required for efficient replication in nonhuman primatesEmmalene J Bartlett
Laboratory of Infectious Diseases, Respiratory Viruses Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, U S Department of Health and Human Services, Bethesda, Maryland 20892 8007, USA
J Virol 82:8965-77. 2008..Thus, the C proteins of HPIV1 are nonessential but have anti-IFN and antiapoptosis activities required for virulence in primates... - A paramyxovirus-vectored intranasal vaccine against Ebola virus is immunogenic in vector-immune animalsLijuan Yang
Laboratory of Infectious Disease, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 50 South Drive, Rm 6505, Bethesda, Maryland 20892 8007, USA
Virology 377:255-64. 2008.... - Targeted mutagenesis as a rational approach to dengue virus vaccine developmentJoseph E Blaney
Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 33 North Drive, Room 3W10A, Bethesda, MD 20892 3203, USA
Curr Top Microbiol Immunol 338:145-58. 2010..Clinical studies of rDEN4Delta30-4995 are ongoing... - Attenuating mutations in the P/C gene of human parainfluenza virus type 1 (HPIV1) vaccine candidates abrogate the inhibition of both induction and signaling of type I interferon (IFN) by wild-type HPIV1William Van Cleve
Laboratory of Infectious Diseases, Respiratory Viruses Section, NIH, Bldg 50, Room 6511 50 South Drive MSC 8007 Bethesda, MD 20892 8007, USA
Virology 352:61-73. 2006.... - Frequent frameshift and point mutations in the SH gene of human metapneumovirus passaged in vitroStephane Biacchesi
Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland 20892 8007, USA
J Virol 81:6057-67. 2007..Adaptation involving the functional loss of a gene is unusual for an RNA virus... - Delivery to the lower respiratory tract is required for effective immunization with Newcastle disease virus-vectored vaccines intended for humansJoshua M DiNapoli
Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 8007, USA
Vaccine 27:1530-9. 2009.... - Comparison of live and inactivated tick-borne encephalitis virus vaccines for safety, immunogenicity and efficacy in rhesus monkeysAlexander A Rumyantsev
Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, MSC 8133, Bethesda, MD 20892-8133, USA
Vaccine 24:133-43. 2006..These results indicate that both TBEV/DEN4Delta30 and LGT/DEN4 are safe and efficacious in rhesus monkeys and should be further evaluated as vaccine candidates for use in humans... - Newcastle disease virus, a host range-restricted virus, as a vaccine vector for intranasal immunization against emerging pathogensJoshua M DiNapoli
Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
Proc Natl Acad Sci U S A 104:9788-93. 2007..NDV has the potential for further development as a pretested, highly attenuated, intranasal vector to be available for expedited vaccine development for humans, who generally lack preexisting immunity against NDV... - Growth restriction of an experimental live attenuated human parainfluenza virus type 2 vaccine in human ciliated airway epithelium in vitro parallels attenuation in African green monkeysAnne Schaap-Nutt
Laboratory of Infectious Diseases, RNA Viruses Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892 2007, USA
Vaccine 28:2788-98. 2010..This restriction paralleled attenuation in the upper and lower respiratory tract of African green monkeys, supporting the HAE model as an appropriate and convenient system for characterizing HPIV2 vaccine candidates... - Live-attenuated virus vaccines for respiratory syncytial and parainfluenza viruses: applications of reverse geneticsBrian R Murphy
Respiratory Viruses Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases/NIH, Building 50, Room 6517, 50 South Drive MSC 8007, Bethesda, MD 20892, USA
J Clin Invest 110:21-7. 2002 - The live attenuated dengue serotype 1 vaccine rDEN1Delta30 is safe and highly immunogenic in healthy adult volunteersAnna P Durbin
Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
Hum Vaccin 2:167-73. 2006..These promising preclinical studies have identified rDEN1Delta30 as a candidate DEN1 vaccine virus for further testing in a human Phase I clinical trial... - Codon stabilization analysis of the "248" temperature sensitive mutation for increased phenotypic stability of respiratory syncytial virus vaccine candidatesCindy Luongo
Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892 8007, USA
Vaccine 27:5667-76. 2009.... - Immunization of primates with a Newcastle disease virus-vectored vaccine via the respiratory tract induces a high titer of serum neutralizing antibodies against highly pathogenic avian influenza virusJoshua M DiNapoli
Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases NIH, 50 South Drive, Bethesda, MD 20892, USA
J Virol 81:11560-8. 2007..This vaccine is a candidate for clinical evaluation in humans... - Principles underlying the development and use of live attenuated cold-adapted influenza A and B virus vaccinesBrian R Murphy
Respiratory Viruses Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892-8007, USA
Viral Immunol 15:295-323. 2002 - Phase I clinical evaluation of rDEN4Delta30-200,201: a live attenuated dengue 4 vaccine candidate designed for decreased hepatotoxicityJulie H McArthur
Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
Am J Trop Med Hyg 79:678-84. 2008..The rDEN4Delta30-200,201 is a promising candidate and can be considered for inclusion in a tetravalent dengue virus (DENV) vaccine... - The C proteins of human parainfluenza virus type 1 (HPIV1) control the transcription of a broad array of cellular genes that would otherwise respond to HPIV1 infectionJim B Boonyaratanakornkit
Laboratory of Infectious Diseases, Respiratory Viruses Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20892 8007, USA
J Virol 83:1892-910. 2009..Thus, changes in host cell transcription did not reflect the striking phenotypic differences observed between these two viruses... - Role of interferon in the replication of human parainfluenza virus type 1 wild type and mutant viruses in human ciliated airway epitheliumEmmalene J Bartlett
Laboratory of Infectious Diseases, Respiratory Viruses Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20892 2007, USA
J Virol 82:8059-70. 2008.... - Reappraisal of the association of intussusception with the licensed live rotavirus vaccine challenges initial conclusionsBrian R Murphy
National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
J Infect Dis 187:1301-8. 2003 - Recombinant human parainfluenza virus type 2 with mutations in V that permit cellular interferon signaling are not attenuated in non-human primatesAnne Schaap-Nutt
Laboratory of Infectious Diseases, RNA Viruses Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA
Virology 406:65-79. 2010..This indicates that loss of HPIV2's ability to inhibit IFN signaling is insufficient to attenuate virus replication in vivo as long as IFN induction is still inhibited... - Prospects for a dengue virus vaccineStephen S Whitehead
Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
Nat Rev Microbiol 5:518-28. 2007..In this Review we discuss the unique immunological concerns in dengue virus vaccine development and the current prospects for the development of an acceptable vaccine, a goal that is likely to be reached in the near future... - The neurovirulence and neuroinvasiveness of chimeric tick-borne encephalitis/dengue virus can be attenuated by introducing defined mutations into the envelope and NS5 protein genes and the 3' non-coding region of the genomeAmber R Engel
Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
Virology 405:243-52. 2010..The high level of safety in the central nervous system indicates that vDelta30/E(315)/NS5(654,655) should be further evaluated as a TBEV vaccine... - Cellular inflammatory response to flaviviruses in the central nervous system of a primate hostOlga A Maximova
Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892 3203, USA
J Histochem Cytochem 57:973-89. 2009.... - Paired charge-to-alanine mutagenesis of dengue virus type 4 NS5 generates mutants with temperature-sensitive, host range, and mouse attenuation phenotypesKathryn A Hanley
Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
J Virol 76:525-31. 2002..This large set of charge-to-alanine mutations specifying a wide range of attenuation for mouse brain should prove useful in fine-tuning recombinant live attenuated DEN vaccines... - The secreted form of respiratory syncytial virus G glycoprotein helps the virus evade antibody-mediated restriction of replication by acting as an antigen decoy and through effects on Fc receptor-bearing leukocytesAlexander Bukreyev
LID, NIAID, NIH, 50 South Drive, Room 6505, Bethesda, MD 20892 8007, USA
J Virol 82:12191-204. 2008..Thus, sG helps RSV escape the antibody-dependent restriction of replication via effects as an antigen decoy and as a modulator of leukocytes bearing Fc gamma receptors... - Dengue virus type 3 vaccine candidates generated by introduction of deletions in the 3' untranslated region (3'-UTR) or by exchange of the DENV-3 3'-UTR with that of DENV-4Joseph E Blaney
Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, United States
Vaccine 26:817-28. 2008..In addition, rDEN3Delta30/31 had reduced replication in Toxorynchites mosquitoes following intrathoracic inoculation. The results are discussed in the context of vaccine development and the physical structure of the DENV 3'-UTR... - Live vaccines for human metapneumovirus designed by reverse geneticsUrsula J Buchholz
Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Building 50, Room 6505, 50 South Dr MSC 8007, Bethesda, MD 20892 8007, USA
Expert Rev Vaccines 5:695-706. 2006..Additional modifications to provide improved vaccines will also be discussed... - Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARSAlexander Bukreyev
Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
Lancet 363:2122-7. 2004..We have developed an experimental SARS vaccine for direct immunisation of the respiratory tract, the major site of SARS- coronavirus transmission and disease... - Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunityUrsula J Buchholz
Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 8007, USA
Proc Natl Acad Sci U S A 101:9804-9. 2004.... - The two major human metapneumovirus genetic lineages are highly related antigenically, and the fusion (F) protein is a major contributor to this antigenic relatednessMario H Skiadopoulos
Respiratory Viruses Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Disease, National Institutes of Health, Building 50, Room 6511, 50 South Dr, MSC 8007, Bethesda, MD 20892 8007, USA
J Virol 78:6927-37. 2004.... - Genetic diversity between human metapneumovirus subgroupsStephane Biacchesi
Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 8007, USA
Virology 315:1-9. 2003..It is reasonable to anticipate that the two genetic subgroups of HMPV represent antigenic subgroups approximately comparable to those of HRSV... - Substitution of the structural genes of dengue virus type 4 with those of type 2 results in chimeric vaccine candidates which are attenuated for mosquitoes, mice, and rhesus monkeysStephen S Whitehead
Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Room 6515, Building 50, 50 South Drive, Bethesda, MD 20892 8007, USA
Vaccine 21:4307-16. 2003.... - A trade-off in replication in mosquito versus mammalian systems conferred by a point mutation in the NS4B protein of dengue virus type 4Kathryn A Hanley
Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
Virology 312:222-32. 2003..The opposing effects of the NS4B P101L mutation in mosquito and vertebrate systems suggest that the NS4B protein is involved in maintaining the balance between efficient replication in the mosquito vector and the human host... - A live, attenuated dengue virus type 1 vaccine candidate with a 30-nucleotide deletion in the 3' untranslated region is highly attenuated and immunogenic in monkeysStephen S Whitehead
Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
J Virol 77:1653-7. 2003..The ability of the Delta30 mutation to attenuate both DEN1 and DEN4 viruses suggests that a tetravalent DEN vaccine could be generated by introduction of the Delta30 mutation into wt DEN viruses belonging to each of the four serotypes... - More antibody with less antigen: can immunogenicity of attenuated live virus vaccines be improved?Alexander Bukreyev
Respiratory Viruses Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 50 South Drive, Room 6517, Bethesda, MD 20892, USA
Proc Natl Acad Sci U S A 99:16987-91. 2002..Thus, it might be possible to develop live-attenuated vaccines that are as immunogenic as parental WT virus or, possibly, even more so... - The genome length of human parainfluenza virus type 2 follows the rule of six, and recombinant viruses recovered from non-polyhexameric-length antigenomic cDNAs contain a biased distribution of correcting mutationsMario H Skiadopoulos
Respiratory Viruses Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
J Virol 77:270-9. 2003..These results demonstrate, in the context of complete infectious virus, that HPIV2 has a strong and seemingly absolute requirement for a polyhexameric genome... - Sendai virus, a murine parainfluenza virus type 1, replicates to a level similar to human PIV1 in the upper and lower respiratory tract of African green monkeys and chimpanzeesMario H Skiadopoulos
Respiratory Viruses Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
Virology 297:153-60. 2002..Its ability to efficiently replicate in nonhuman primates suggests that MPIV1 lacks a significant host range restriction in primates and could theoretically cause zoonotic disease in humans... - Evaluation of the replication and immunogenicity of recombinant human parainfluenza virus type 3 vectors expressing up to three foreign glycoproteinsMario H Skiadopoulos
Respiratory Viruses Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
Virology 297:136-52. 2002..Thus, it is possible to use a single HPIV vector expressing two foreign gene inserts to protect infants and young children from the severe lower respiratory tract disease caused by the three major human PIV pathogens... - Genetically modified, live attenuated dengue virus type 3 vaccine candidatesJoseph E Blaney
Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892 8007, USA
Am J Trop Med Hyg 71:811-21. 2004..Thus, the rDEN3/4(ME) and rDEN3/4Delta30(ME) antigenic chimeric viruses can be considered for evaluation in humans and for inclusion in a tetravalent dengue vaccine... - Deletion of M2 gene open reading frames 1 and 2 of human metapneumovirus: effects on RNA synthesis, attenuation, and immunogenicityUrsula J Buchholz
Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 8007, USA
J Virol 79:6588-97. 2005..The HMPV rdeltaM2-2 virus is a promising and highly attenuated HMPV vaccine candidate... - Sequence analysis of the Washington/1964 strain of human parainfluenza virus type 1 (HPIV1) and recovery and characterization of wild-type recombinant HPIV1 produced by reverse geneticsJason T Newman
National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 0720, USA
Virus Genes 24:77-92. 2002..This rHPIV1 can now be used to study the biological properties of HPIV1 and as a substrate to introduce attenuating mutations for the generation of live-attenuated HPIV1 vaccine candidates... - Nonsegmented negative-strand viruses as vaccine vectorsAlexander Bukreyev
Building 50, Room 6505, NIAID, NIH, 50 South Dr, MSC 8007, Bethesda, MD 20892-8007, USA
J Virol 80:10293-306. 2006 - Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeysJoseph E Blaney
Laboratory of Infectious Diseases, NIH, NIAID, LID Twinbrook III, Room 3W 13, 12735 Twinbrook Parkway, MSC 8133, Bethesda, MD 20892 8133, USA
J Virol 79:5516-28. 2005..However, two doses of TV-2 or TV-3 induced protection against DEN2 challenge. Two tetravalent formulations, TV-2 and TV-3, possess properties of a successful DEN vaccine and can be considered for evaluation in clinical trials... - Introducing point and deletion mutations into the P/C gene of human parainfluenza virus type 1 (HPIV1) by reverse genetics generates attenuated and efficacious vaccine candidatesEmmalene J Bartlett
Laboratory of Infectious Diseases, Respiratory Viruses Section, National Institute of Allergy and Infectious Diseases, National Institute of Health, Department of Health and Human Services, Bethesda, MD 20892 8007, USA
Vaccine 24:2674-84. 2006..This virus will be evaluated clinically as a live intranasal HPIV1 vaccine, one that can be further attenuated as necessary by the introduction of additional stabilized att mutations previously developed in the L protein... - Individual contributions of the human metapneumovirus F, G, and SH surface glycoproteins to the induction of neutralizing antibodies and protective immunityMario H Skiadopoulos
Respiratory Viruses Section, Laboratory of Infectious Diseases, NIAID, NIH, DHHS, Bethesda, MD 20892 8007, USA
Virology 345:492-501. 2006..Also, although the SH protein of HMPV is a virion protein that is much larger than its counterparts in previously studied paramyxoviruses, it does not appear to be a significant neutralization or protective antigen... - Recombinant newcastle disease virus expressing a foreign viral antigen is attenuated and highly immunogenic in primatesAlexander Bukreyev
LID, NIAID, NIH, 50 South Dr, Rm 6505, Bethesda, MD 20892 8007, USA
J Virol 79:13275-84. 2005..NDV appears to be a promising vector for the development of vaccines for humans; one application would be in controlling localized outbreaks of emerging pathogens... - Live-attenuated intranasal parainfluenza virus type 2 vaccine candidates developed by reverse genetics containing L polymerase protein mutations imported from heterologous paramyxovirusesSheila M Nolan
Laboratory of Infectious Diseases, Respiratory Viruses Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 50 South Drive, Building 50, Room 6509, MSC 8007, Bethesda, MD 20892, USA
Vaccine 23:4765-74. 2005..rHPIV2s bearing these modified mutations exhibited enhanced attenuation. The genetically stabilized mutations conferring a high level of attenuation will be useful in generating a live-attenuated virus vaccine for HPIV2... - Evaluation of the Langat/dengue 4 chimeric virus as a live attenuated tick-borne encephalitis vaccine for safety and immunogenicity in healthy adult volunteersPeter F Wright
Department of Pediatrics, Division of Pediatric Infectious Disease, Vanderbilt University Medical Center, Nashville, TN, USA
Vaccine 26:882-90. 2008..To provide a sufficient level of immunity to widely prevalent, highly neurovirulent strains of TBEV in humans, vaccine candidates will likely need to be based on the TBEV structural protein genes... - rDEN2/4Delta30(ME), a live attenuated chimeric dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue-naïve adultsAnna P Durbin
Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA
Hum Vaccin 2:255-60. 2006..The Delta30 mutation remained unchanged in each isolate, confirming the stability of the Delta30 mutation. Further evaluation of this vaccine in a tetravalent formulation is warranted... - Successful topical respiratory tract immunization of primates against Ebola virusAlexander Bukreyev
Laboratory of Infectious Disease, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 8007, USA
J Virol 81:6379-88. 2007..To our knowledge, this is the first study in which topical immunization through respiratory tract achieved prevention of a viral hemorrhagic fever infection in a primate model... - rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteersAnna P Durbin
Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205, USA
J Infect Dis 191:710-8. 2005..The live attenuated dengue virus type 4 (DEN-4) vaccine candidate virus rDEN4 Delta 30 was previously found to be safe and immunogenic at a dose of 10(5) plaque-forming units (pfu)... - The interferon antagonist NS2 protein of respiratory syncytial virus is an important virulence determinant for humansPeter F Wright
Division of Pediatric Infectious Disease, Vanderbilt University Medical Center, Nashville, TN 37232, USA
J Infect Dis 193:573-81. 2006..In the present study, the NS2 gene, whose encoded protein antagonizes the host's interferon- alpha / beta response, was deleted from RSV vaccine candidates by use of reverse genetics... - Comparative neuropathogenesis and neurovirulence of attenuated flaviviruses in nonhuman primatesOlga A Maximova
Center for Biologics Evaluation and Research, U S Food and Drug Administration, Rockville, Maryland 20852, USA
J Virol 82:5255-68. 2008..These results provide insight into the neuropathogenesis associated with attenuated flaviviruses that may guide the design of safe vaccines... - A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infantsRuth A Karron
Pediatr Infect Dis J 22:394-405. 2003..ca revertants were not detected. CONCLUSIONS: The cp-45 vaccine is appropriately attenuated and immunogenic in infants as young as 1 month of age. Further development of this vaccine is warranted... - Transmissibility, infectivity and immunogenicity of a live human parainfluenza type 3 virus vaccine (HPIV3cp45) among susceptible infants and toddlersShabir A Madhi
University of the Witwatersrand Medical Research Council Respiratory and Meningeal Pathogens Research Unit, South Africa
Vaccine 24:2432-9. 2006..This study examined the transmissibility between young children of an intranasally administered live attenuated human parainfluenza virus type 3 (HPIV3)-cp45 vaccine candidate... - What are the risks--hypothetical and observed--of recombination involving live vaccines and vaccine vectors based on nonsegmented negative-strain RNA viruses?Peter L Collins
J Virol 82:9805-6. 2008 - An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirusElisabetta Traggiai
Institute for Research in Biomedicine, Via Vela 6, CH 6500 Belllinzona, Switzerland
Nat Med 10:871-5. 2004..These results show that it is possible to interrogate the memory repertoire of immune donors to rapidly and efficiently isolate neutralizing antibodies that have been selected in the course of natural infection... - Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infantsRuth A Karron
Center for Immunization Research, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland 21205, USA
J Infect Dis 191:1093-104. 2005..Recombination technology can be used to create live attenuated respiratory syncytial virus (RSV) vaccines that contain combinations of known attenuating mutations...